HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $48.
September 19, 2023 | 10:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enanta Pharma's stock is likely to be positively impacted by the reiterated 'Buy' rating and maintained price target of $48 by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence a stock's performance. A reiterated 'Buy' rating indicates the analyst's continued confidence in the company's prospects, which can boost investor sentiment and drive the stock price up. The maintained price target of $48 also suggests that the analyst believes the stock is undervalued at current levels, which can further encourage buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100